Physician profile
Bryan Guignon
NPI 1831551555
$3,572.68
in general payments reported to CMS, 2019-2025
12 companies · $237 in 2025
The $237 reported for 2025 was less than what a typical Podiatrist provider received nationally (typical 2025 total: $260).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $364 · 2020: $119 · 2021: $11.30 · 2022: $296 · 2023: $1,363 · 2024: $1,182 · 2025: $237.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $2,119 · Food and Beverage: $664.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $2,118.70 |
| Food and Beverage | $663.52 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Stryker Corporation | $1,766.65 | 2019-2025 | Prostep, Augment Injectable, Easyfuse |
| Elite Orthopedics, LLC | $1,388.92 | 2019-2025 | |
| Organogenesis INC. | $120.63 | 2019 | |
| Kci USA, INC. | $98.98 | 2019 | |
| Wright Medical Technology, INC. | $68.20 | 2020 | |
| Averitas Pharma INC. | $40.78 | 2023-2024 | Qutenza |
| Bsn Medical INC | $21.94 | 2025 | |
| Astrazeneca Pharmaceuticals LP | $20.90 | 2019 | |
| Paragon 28, INC. | $13.22 | 2023 | Mtp |
| Novo Nordisk INC | $11.30 | 2021 | |
| Misonix INC | $11.20 | 2020 | |
| Biocomposites INC | $9.96 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bryan Guignon listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.